207940.KS

Samsung Biologics Co.,Ltd. [207940.KS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

207940.KS Stock Summary

Earnings have grown 23.1% per last year.

Top 10 Correlated ETFs

207940.KS

Top 10 Correlated Stocks

207940.KS

In the News

207940.KS Financial details

Company Rating

Market Cap

56227.46B

Income

857.69B

Revenue

3694.59B

Book val./share

Cash/share

Dividend

Dividend %

Employees

4.28K

Optionable

Shortable

Yes

Earnings

22 Apr 2024

P/E

56.29

Forward P/E

PEG

105.82

P/S

14.8

P/B

5.52

P/C

P/FCF

430.66

Quick Ratio

Current Ratio

1.32

Debt / Equity

LT Debt / Equity

EPS (TTM)

12.05K

EPS next Y

EPS next Q

EPS this Y

5.31%

EPS next Y

EPS next 5Y

EPS last 5Y

31.76%

Revenue last 5Y

39.41%

Revenue Q/Q

3.82%

EPS Q/Q

20.93%

SMA20

-7.96%

SMA50

10.37%

SMA100

6.08%

Inst Own

Inst Trans

ROA

ROE

10%

ROC

0.1%

Gross Margin

48%

Oper. Margin

33%

Profit Margin

26%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

668000.0-880000.0

52W High

+96.93%

52W Low

+159.43%

RSI

50.88

Rel Volume

0.47

Avg Volume

74.87K

Volume

35.19K

Perf Week

4.08%

Perf Month

-7.69%

Perf Quarter

12.83%

Perf Half Y

12.26%

Beta

0.511

Volatility

39346.19%, 101265.23%

Prev Close

-0.29%

Price

1733000

Change

-0.97%

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 74.87K
Market Capitalization 56227.46B
Employee 4.28K
CEO Mr. John Chongbo Rim
Headquarters Incheon,KR
IPO Date 2016-11-11
Website https://samsungbiologics.com

Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.